Blackhawk Capital Partners LLC. Buys 6,851 Shares of Johnson & Johnson (NYSE:JNJ)

Blackhawk Capital Partners LLC. increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 409.5% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 8,524 shares of the company's stock after acquiring an additional 6,851 shares during the quarter. Blackhawk Capital Partners LLC.'s holdings in Johnson & Johnson were worth $1,414,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. WealthTrak Capital Management LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $26,000. Mountain Hill Investment Partners Corp. bought a new position in Johnson & Johnson in the 4th quarter worth about $29,000. Conquis Financial LLC bought a new position in Johnson & Johnson in the 4th quarter worth about $33,000. Bernard Wealth Management Corp. bought a new position in Johnson & Johnson in the 4th quarter worth about $36,000. Finally, Runnymede Capital Advisors Inc. bought a new stake in shares of Johnson & Johnson during the 4th quarter valued at about $38,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Trading Down 0.5%

Shares of JNJ traded down $0.82 during mid-day trading on Friday, hitting $156.87. 7,866,488 shares of the company's stock traded hands, compared to its average volume of 8,077,942. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm has a market capitalization of $377.44 billion, a P/E ratio of 17.45, a PEG ratio of 2.14 and a beta of 0.41. The business's 50-day moving average price is $153.75 and its 200-day moving average price is $154.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, beating the consensus estimate of $2.59 by $0.18. Johnson & Johnson had a return on equity of 33.46% and a net margin of 24.42%. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Investors of record on Tuesday, May 27th were given a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.31%. Johnson & Johnson's payout ratio is currently 57.84%.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on JNJ shares. Wall Street Zen upgraded Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Saturday, June 21st. Leerink Partnrs downgraded Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, May 13th. Raymond James Financial dropped their price target on Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating for the company in a research report on Monday, April 14th. Morgan Stanley reiterated an "underperform" rating on shares of Johnson & Johnson in a research report on Thursday. Finally, Royal Bank Of Canada reissued an "outperform" rating and set a $181.00 price objective on shares of Johnson & Johnson in a report on Thursday, June 5th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $171.00.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.